GPER G-1 Development Group

GPER G-1 Development Group is a biotechnology company focused on developing novel small molecule therapeutics targeting the G protein-coupled estrogen receptor (GPER). Spun out from the University of New Mexico, the company's lead candidate is G-1 (Tespria), a selective GPER agonist designed to treat obesity and type 2 diabetes by restoring insulin sensitivity and promoting weight loss without the feminizing effects of classical estrogen. The company also holds a portfolio of GPER modulators, including antagonists G15 and G36, for potential applications in cardiovascular and kidney diseases. GPER G-1 Development Group is a portfolio company of the New Mexico Start-Up Factory and operates in close collaboration with academic researchers to translate GPER-related discoveries into clinical therapies.